Fast Market Research

"Inflammatory Bowel Disease - Pipeline Review, H1 2014" Published

Fast Market Research recommends "Inflammatory Bowel Disease - Pipeline Review, H1 2014" from Global Markets Direct, now available


Boston, MA -- (SBWIRE) -- 05/14/2014 -- Inflammatory Bowel Disease - Pipeline Review, H1 2014


Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H1 2014', provides an overview of the Inflammatory Bowel Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects.

View Full Report Details and Table of Contents

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Inflammatory Bowel Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Inflammatory Bowel Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

Companies Mentioned in this Report: Boehringer Ingelheim GmbH, Amgen Inc., Sanofi, Athersys, Inc., GlaxoSmithKline plc, Biotec Pharmacon ASA, Emergent BioSolutions Inc., Takeda Pharmaceutical Company Limited, BioLineRx, Ltd., TiGenix NV, ASKA Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Paratek Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., 4SC AG, Addex Therapeutics, AlbireoPharma, iCo Therapeutics Inc., Basilea Pharmaceutica AG, Compugen Ltd., Pluristem Therapeutics Inc., Galapagos NV, Synta Pharmaceuticals Corp., Sareum Holdings plc, Sucampo Pharmaceuticals, Inc., MetrioPharm AG, Advinus Therapeutics Ltd., Affimed Therapeutics AG, Axxam SpA, ActogeniX NV, Omni Bio Pharmaceutical Inc., Am-Pharma B.V., Jenrin Discovery, Inc., Upsher-Smith Laboratories, Inc., Ventria Bioscience, Aquinox Pharmaceuticals Inc., Argos Therapeutics, Inc., Catabasis Pharmaceuticals, Inc., Opsona Therapeutics Ltd., Inotek Pharmaceuticals Corporation, Zealand Pharma A/S, Giuliani S.p.A., Vitae Pharmaceuticals, Inc., Kyorin Pharmaceutical Co., Ltd., Synergy Pharmaceuticals, Inc., Ensemble Discovery Corporation, Celsus Therapeutics Plc, Medestea Research & Production S.p.A., Antibe Therapeutics, Inc., Nephrx Corporation, SunTen Phytotech Co., Ltd., Ferring Pharmaceuticals, Inc., Janssen Biotech, Inc., Protagonist Therapeutics Inc., Lycera Corp., Pepscan Therapeutics, N30 Pharmaceuticals, GlycoMar Limited, RaQualia Pharma Inc., Atlantic Healthcare Limited, Sigmoid Pharma Ltd., ProNoxis AB, ProtAb Ltd, Complix NV, Amakem NV, Delenex Therapeutics AG, Creabilis SA, SK Biopharmaceuticals Co., Ltd., ReveraGen BioPharma, Inc., ChironWells GmbH, GT Biologics Limited

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Inflammatory Bowel Disease - Pipeline Review, H1 2013
- Crohn's Disease - Pipeline Review, H1 2014
- Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2014
- Parkinson's Disease - Pipeline Review, H1 2014
- Alzheimer's Disease - Pipeline Review, H1 2014
- Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014
- Inflammatory Pain - Pipeline Review, H1 2014
- Huntington's Disease - Pipeline Review, H1 2014
- Irritable Bowel Syndrome - Pipeline Review, H1 2014
- Ulcerative Colitis - Pipeline Review, H1 2014